RxDoctor Payments Data

Letha Sunil, PA

Physician Assistant · Olney, MDNPI 1053952531

Payments from drug & device makers

$2,404in general payments, 2019–2025

Across 112 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$998
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$416
  • Supernus Pharmaceuticals, Inc.$263
  • Takeda Pharmaceuticals U.S.A., Inc.$231
  • Lundbeck LLC$190
  • Otsuka America Pharmaceutical, Inc.$165
  • plus $141 from 2 others

What the payments were for

  • Food & beverage$2,397100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,404 in reported general payments places this provider in the 85th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$8,101
Medicare patients
48
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl20$35,564
TrintellixVortioxetine Hydrobromide19$13,879
Lurasidone Hcl13$10,967
Bupropion XlBupropion Hcl67$2,731
Aripiprazole36$2,438
Divalproex Sodium35$1,639
Lamotrigine59$1,348
Buspirone Hcl53$1,211
Escitalopram Oxalate75$1,210
Trazodone Hcl86$1,149
Duloxetine Hcl48$1,077
Quetiapine Fumarate32$784
Naltrexone Hcl11$711
Clonazepam68$635
Fluoxetine Hcl76$630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$998$35,56420 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$231$13,87919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Olney

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →